Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005

Jaap Verweij, Paolo G. Casali, Dusan Kotasek, Axel Le Cesne, Peter Reichard, Ian R. Judson, R. Issels, Allan T. van Oosterom, Martine Van Glabbeke, Jean Yves Blay

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

Original languageEnglish
Pages (from-to)974-978
Number of pages5
JournalEuropean Journal of Cancer
Volume43
Issue number6
DOIs
Publication statusPublished - Apr 2007

Fingerprint

Gastrointestinal Stromal Tumors
Imatinib Mesylate
Prospective Studies
Population

Keywords

  • Cardiotoxicity
  • GIST
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients : Analyis of EORTC-ISG-AGITG study 62005. / Verweij, Jaap; Casali, Paolo G.; Kotasek, Dusan; Le Cesne, Axel; Reichard, Peter; Judson, Ian R.; Issels, R.; van Oosterom, Allan T.; Van Glabbeke, Martine; Blay, Jean Yves.

In: European Journal of Cancer, Vol. 43, No. 6, 04.2007, p. 974-978.

Research output: Contribution to journalArticle

Verweij, J, Casali, PG, Kotasek, D, Le Cesne, A, Reichard, P, Judson, IR, Issels, R, van Oosterom, AT, Van Glabbeke, M & Blay, JY 2007, 'Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005', European Journal of Cancer, vol. 43, no. 6, pp. 974-978. https://doi.org/10.1016/j.ejca.2007.01.018
Verweij, Jaap ; Casali, Paolo G. ; Kotasek, Dusan ; Le Cesne, Axel ; Reichard, Peter ; Judson, Ian R. ; Issels, R. ; van Oosterom, Allan T. ; Van Glabbeke, Martine ; Blay, Jean Yves. / Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients : Analyis of EORTC-ISG-AGITG study 62005. In: European Journal of Cancer. 2007 ; Vol. 43, No. 6. pp. 974-978.
@article{3a6495ff31fe4aaa8cd478c2dcade559,
title = "Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analyis of EORTC-ISG-AGITG study 62005",
abstract = "Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2{\%}) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.",
keywords = "Cardiotoxicity, GIST, Imatinib",
author = "Jaap Verweij and Casali, {Paolo G.} and Dusan Kotasek and {Le Cesne}, Axel and Peter Reichard and Judson, {Ian R.} and R. Issels and {van Oosterom}, {Allan T.} and {Van Glabbeke}, Martine and Blay, {Jean Yves}",
year = "2007",
month = "4",
doi = "10.1016/j.ejca.2007.01.018",
language = "English",
volume = "43",
pages = "974--978",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients

T2 - Analyis of EORTC-ISG-AGITG study 62005

AU - Verweij, Jaap

AU - Casali, Paolo G.

AU - Kotasek, Dusan

AU - Le Cesne, Axel

AU - Reichard, Peter

AU - Judson, Ian R.

AU - Issels, R.

AU - van Oosterom, Allan T.

AU - Van Glabbeke, Martine

AU - Blay, Jean Yves

PY - 2007/4

Y1 - 2007/4

N2 - Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

AB - Recent publications have suggested that imatinib (Glivec) may be cardiotoxic. We have therefore assessed the largest study on the agent performed in patients with gastrointestinal stromal tumours, randomising a daily dose of 400 mg versus 800 mg. 946 Patients were entered, 942 patients received at least one dose of imatinib. The median time on treatment was 24 months. A total of 24,574 exposure months could be analysed. We could not identify an excess of cardiac events in the study population. In 2 patients (0.2%) a possible cardiotoxic effect of imatinib could not fully be excluded. The current analysis of a large randomised prospective study could not confirm previous suggestions of imatinib induced cardiac toxicity.

KW - Cardiotoxicity

KW - GIST

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=33947722204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947722204&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2007.01.018

DO - 10.1016/j.ejca.2007.01.018

M3 - Article

C2 - 17336514

AN - SCOPUS:33947722204

VL - 43

SP - 974

EP - 978

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -